Abstract:Background: Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remains a significant challenge. Objective: The primary objective of this review is to highlight the clinical significance of multimodality fusion neuroimaging for the determination of: pharmacokinetics and pre-clinical development of radiopharmaceuticals (RPs); in-vivo monitoring of stem cell transplantation therapy; nicotinic acetylcholine receptors (nAChRs) investigations; and regional cerebral blood flow and glucose metabolism in cognitively-impaired subjects employing multimodality noninvasive PET, CT, MRI/MRS, and SPECT imaging. Method: Recent methodology to perform multimodality imaging employing computer-based fusion algorithms is provided with a primary emphasis on nanoSPECT/CT, PET-CT, and PET-MRI in experimental animals. Multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT. Furthermore, limitations of individual neuroimaging system, body movements due to cardiorespiratory activity, and co-registration of multimodality neuroimaging data are described. Results: Multimodality neuroimaging is clinically-significant because it emphasizes the importance of complementary imaging for theranostic applications and minimizes the inherent limitations of individual neuroimaging approach. However, it may increase the radiation dose to a susceptible pediatric population. Conclusion: Future developments in specific RPs with minimum radiation exposure will facilitate early differential diagnosis, prevent, slowdown and/or cure neurodegenerative diseases, cardiovascular diseases, and cancer. Eventually, conventional and functional neuroimaging, combined with clinical, laboratory and - omics analyses will facilitate theranostics to accomplish the ultimate goal of personalized medicine.

Paradigm shift required for translational research on the brain

Translational Neuroscience: Toward New Therapies

Rapid Progress in Neuroimaging Technologies Fuels Central Nervous System Translational Medicine

A perspective on translating genomic discoveries into targets for brain-machine interface and deep brain stimulation devices

Recent Technical Advances in Accelerating the Clinical Translation of Small Animal Brain Imaging: Hybrid Imaging, Deep Learning, and Transcriptomics

Advances in neuroimaging to support translational medicine in dementia

Current Challenges in Translational and Clinical fMRI and Future Directions

Advanced Neuroscience Technologies

A Paradigm Shift in Neuroscience Driven by Big Data: State of art, Challenges, and Proof of Concept

Translational Multimodality Neuroimaging

Introduction and recent progress of BRAIN Initiative in the United States

Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic

Large-scale neurophysiology and single-cell profiling in human neuroscience

Real-World Neuroimaging Technologies

Mind Unveiled: Cutting-Edge Neuroscience and Precision Brain Mapping

Translating striatal activity from brain slice to whole animal neurophysiology: A guide for neuroscience research integrating diverse levels of analysis

Coming full circle: In vivo Veritas, or expanding the neuroscience frontier

The personal brain

Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry

The coming decade of digital brain research: A vision for neuroscience at the intersection of technology and computing

Building better biomarkers: brain models in translational neuroimaging